Establishing Biosimilarity: Regulatory and Scientific Expectations
A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences in terms of safety, purity,…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials
Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…